Let's talk medical research

We’re thrilled to share that our CEO, Laurent Schockmel, has been named a top 40 Healthcare Transformer by Medical Marketing & Media (MM&M). This honor is given to visionaries driving innovation at the intersection of healthcare and technology, and it’s exciting to see Laurent in such great company. Laurent took the helm as CEO of Antidote in 2018 with the objective of harnessing our ...

Antidote recently conducted a survey with SCORR Marketing through which we asked nearly 4,000 patients about their perspectives on clinical trials. One key finding: patients with different conditions have different opinions on taking part in medical research. For example, in the survey, people with melanoma were joining clinical trials to extend their own lives, while those with lupus or kidney ...

With medicine getting ever more targeted and precise, clinical trial protocols are becoming more complex than ever before. While this allows for appropriate evaluation of potential treatment options, it also means that finding patients to take part in trials is increasingly challenging, and the need to look beyond traditional methods of recruitment has become clear.

During a Q3 2018 survey conducted by Antidote Technologies and SCORR Marketing, we explored specific participation stimuli to determine what could make patients consider participating in a clinical trial – and how these motivations varied by condition area.

Despite decades of research, heart disease continues to be the leading cause of death for both men and women in the United States. It’s clear that tackling cardiovascular disease requires a new approach. That’s why today, researchers and heart health advocates are taking on heart disease, stroke, and other conditions from a variety of angles, from exploring precision medicine to driving clinical ...

The majority of clinical trials don't reach their clinical trial patient recruitment targets on time. Meeting a deadline can feel like a lost cause, and beating one can seem impossible. Accelerating recruitment timelines can sound unrealistic, but it's possible – and worth striving for. Even saving just a few months can put your trial on track to improve costs, reduce the burden on research ...

A significant amount of effort goes into recruiting a patient for a clinical trial, including creating IRB-approved materials, reaching the patient population, and setting up a variety of ads to find what performs best. But once a patient expresses interest in a trial and is screened online, it can be difficult to see what steps the patient takes next – unless your patient recruitment company ...

For years, clinical trial patient recruitment has looked the same: identify eligibility criteria for a single trial, conduct traditional media outreach, screen patients for that trial, and hope for the best. Increasingly, however, sponsors have been turning to technology, getting more specific in their outreach and therefore becoming more successful in their recruiting not just for one trial, but ...

Clinical trials are increasing in complexity as the volume of available patient data grows. Today, trials may seek out patients with specific genetic mutations or lab values from a blood test. And while the science behind these requirements may be sound, detailed requirements make clinical trial patient recruitment even more difficult for trial sponsors.

One of the most frustrating elements of medical research today is the speed — patients need new treatments now, but often, clinical trials are delayed or closed due to difficulty finding patients to take part. With clinical trial patient recruitment, sponsors can not only meet deadlines, but beat them, bringing new treatments to patients faster. Here, we break down the key reasons to set your ...